GREY:MDCGF - Post by User
Post by
Jentaion May 02, 2011 10:53am
399 Views
Post# 18517471
Pub;ication
Pub;ication
Medicago's piece entitled "Plants As an Innovative and Accelerated Vaccine-Manufacturing Solution. A plant-based expression system could provide greater speed and capacity at a comparatively low cost," was published in the May 2011 issue of BioPharm International, Volume 24, pp. s27-s30. To access the full article please click here .
ABSTRACT
Medicago has developed a proprietary plant-based manufacturing platform that produces vaccines made of influenza antigen scaffolds (i.e., viruslike particles) that are currently in clinical trials in Canada and the United States. This platform produces vaccine doses within a month of the disclosure of hemagglutinin sequences from emerging strains. It is now being automated and scaled up in North Carolina to bring its surge capacity to more than 10 million doses/month. The platform will be housed in a facility that will be built within 12 months for less than $35 million.